8-K: Aclarion Adjourns Annual Stockholders Meeting to Solicit Additional Votes

Aclarion, Inc. has adjourned its Annual Meeting of Stockholders to July 21, 2025, to allow for the solicitation of additional votes on proposals.

Summary

• Aclarion, Inc. convened its Annual Meeting of Stockholders on July 7, 2025, but immediately adjourned it without transacting any business.
• The purpose of the adjournment is to solicit additional votes for the proposals described in the company's definitive proxy statement, which was filed with the SEC on May 13, 2025.
• The Annual Meeting will be reconvened on Monday, July 21, 2025, at 9:30 a.m. Mountain Time.
• The reconvened meeting will be held at the company's corporate office located at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
• The record date for determining stockholders entitled to vote at the reconvened Annual Meeting remains May 9, 2025.
• Proxies previously submitted for the Annual Meeting will be voted at the adjourned meeting unless properly revoked.
• Stockholders who have already voted and do not wish to change their vote do not need to take further action.
• Stockholders can change their vote by returning a signed proxy with a later date or by transmitting a subsequent vote over the Internet by 11:59 p.m. Mountain Time on July 20, 2025.

Sentiment

Score: 4

Explanation: The adjournment of the annual meeting without transacting business is a negative signal, suggesting insufficient shareholder support for proposals. While the company is taking steps to solicit more votes, it indicates a hurdle. The underlying business focus on healthcare technology and AI is positive, but this specific event is a setback.

Positives

• The company is actively working to ensure shareholder participation and the successful passage of proposals by adjourning the meeting to solicit additional votes.
• Clear instructions are provided for stockholders to vote or change their votes, demonstrating transparency and support for shareholder engagement.
• Aclarion is a healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS), artificial intelligence (AI), and a proprietary biomarker to optimize clinical treatments for low back and neck pain.
• The company is researching the application of AI and machine learning platforms to analyze spectroscopy data for quality control and to evaluate its association with clinical outcomes.

Negatives

• The Annual Meeting was adjourned without transacting any business, indicating a potential lack of sufficient votes to pass the proposals.
• The necessity to solicit additional votes suggests potential challenges in securing adequate shareholder support for the proposals.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause actual operating results to be materially different from any historical results or from any future results expressed or implied.
• Risks and uncertainties are described from time to time in the company's filings with the Securities and Exchange Commission, including those discussed under the heading 'Risk Factors' in their most recently filed reports on Forms 10-K and 10-Q.

Future Outlook

The Annual Meeting will be reconvened on July 21, 2025, to allow for the solicitation of additional votes on the proposals. The company is also researching the application of AI and machine learning platforms to analyze spectroscopy data and evaluate its association with clinical outcomes.

Management Comments

• Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time.

Industry Context

Aclarion operates in the healthcare technology sector, specifically targeting the $134.5 billion U.S. low back and neck pain market. The company's use of Magnetic Resonance Spectroscopy (MRS), artificial intelligence (AI), and proprietary biomarkers aligns with broader industry trends towards data-driven diagnostics and personalized medicine. The research into AI and machine learning for analyzing spectroscopy data indicates a focus on leveraging advanced technologies for improved clinical outcomes and quality control.

Comparison to Industry Standards

• Aclarion's focus on Magnetic Resonance Spectroscopy (MRS) and AI for low back and neck pain positions it within the growing market for non-invasive diagnostic and treatment optimization technologies.
• The $134.5 billion U.S. low back and neck pain market indicates a significant addressable market, comparable to other large chronic pain management sectors where companies like Medtronic (spinal cord stimulation) or Stryker (spinal implants) operate, though Aclarion's approach is diagnostic/treatment optimization rather than direct intervention.
• The application of AI for quality control and analysis of spectroscopy data is consistent with the broader healthcare industry trend of integrating AI for efficiency and improved diagnostic accuracy, similar to how companies like Google Health or IBM Watson Health (though now divested) have explored AI in medical imaging and diagnostics.

Corporate Governance

Stakeholder Impact

• Shareholders: Required to re-engage or confirm their votes for the reconvened meeting; the adjournment may raise concerns about the company's ability to pass key proposals.
• Management: Must actively work to solicit additional votes and ensure the successful passage of proposals at the reconvened meeting.

Next Steps

• Reconvene the Annual Meeting of Stockholders on Monday, July 21, 2025, at 9:30 a.m. Mountain Time.
• Continue soliciting additional votes for the proposals described in the definitive proxy statement.
• Stockholders are encouraged to vote as soon as possible.
• Stockholders can change their vote by returning a signed proxy with a later date or transmitting a subsequent vote over the Internet by 11:59 p.m. Mountain Time on July 20, 2025.

Key Dates

Recommendation

Keywords

Aclarion, ACON, ACONW, Annual Meeting, Stockholders Meeting, Adjournment, Proxy Statement, SEC filing, Healthcare Technology, Magnetic Resonance Spectroscopy, MRS, Artificial Intelligence, AI, Biomarker, Low Back Pain, Neck Pain, Corporate Governance, Shareholder Vote